Interactions between the estrogen receptor, its cofactors and microRNAs in breast cancer Marc P. J. McCaffertyRoisin E. McNeillMichael J. Kerin Review 09 June 2009 Pages: 425 - 432
Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a metanalysis Davide MauriAntonis ValachisLorenzo L. Pesce Review 12 June 2009 Pages: 433 - 439
Glucocorticoid receptor expression in breast cancer associates with older patient age Larissa BelovaBertha DelgadoSuzanne D. Conzen Preclinical Study 31 July 2008 Pages: 441 - 447
Reversal of antiprogestin resistance and progesterone receptor isoform ratio in acquired resistant mammary carcinomas Victoria WargonLuisa A. HelgueroClaudia Lanari Preclinical Study 03 August 2008 Pages: 449 - 460
Characterization of the weak estrogen receptor α agonistic activity of exemestane Selma MasriKi LuiShiuan Chen Preclinical Study 03 August 2008 Pages: 461 - 470
Down-regulation of tumor suppressor gene FEZ1/LZTS1 in breast carcinoma involves promoter methylation and associates with metastasis Ling ChenZhengmao ZhuLi Fu Preclinical Study 07 August 2008 Pages: 471 - 478
Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH Simon A. JoosseErik H. van BeersPetra M. Nederlof Preclinical Study 14 August 2008 Pages: 479 - 489
Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12–93 Olivia PaganiShari Gelberfor the International Breast Cancer Study Group Clinical Trial 25 October 2008 Pages: 491 - 500
Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study C. FalandryM. DebledG. Freyer Clinical Trial 20 November 2008 Pages: 501 - 508
A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial Pascal JézéquelMario CamponeLoïc Campion Clinical Trial 20 November 2008 Pages: 509 - 520
The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer Cynthia R. OsborneAnita DuncanJoyce A. O’Shaughnessy Clinical Trial 13 January 2009 Pages: 521 - 527
Does hormonal therapy decrease tamoxifen associated hot flashes? Debra L. BartonCharles L. Loprinzi Invited Commentary 10 February 2009 Pages: 529 - 530
A pilot study to assess the utility of SPECT/CT-based lymph node imaging to localize lymph nodes that drain the arm in patients undergoing treatment for breast cancer Andrea L. ChevilleIndra DasAbass Alavi Clinical Trial 17 January 2009 Pages: 531 - 538
Identifying the “sentinel lymph nodes” for arm drainage as a strategy for minimizing the lymphedema risk after breast cancer therapy Thomas A. BuchholzRony AvritscherTse-Kuan Yu Invited Commentary 31 January 2009 Pages: 539 - 541
Exploratory study evaluating the association of polymorphisms of angiogenesis genes with hot flashes Bryan P. SchneiderMilan RadovichGeorge W. Sledge Epidemiology 11 September 2008 Pages: 543 - 549
Alcohol and folate intake and breast cancer risk in the WHI Observational Study Christine M. DuffyAnnlouise AssafV. K. Chetty Epidemiology 11 September 2008 Pages: 551 - 562
Evaluating the performance of models for predicting the BRCA germline mutations in Han Chinese familial breast cancer patients Nan-Yan RaoZhen HuZhi-Ming Shao Epidemiology 19 September 2008 Pages: 563 - 570
CCND1 G870A polymorphism contributes to breast cancer susceptibility: a meta-analysis Cheng LuJing DongHongbing Shen Epidemiology 26 September 2008 Pages: 571 - 575
BRCA1/BRCA2 mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany: a population-based study in central Italy Laura OttiniPiera RizzoloDomenico Palli Epidemiology 26 September 2008 Pages: 577 - 586
Daidzein-metabolizing phenotypes in relation to mammographic breast density among premenopausal women in the United States Charlotte AtkinsonKatherine M. NewtonJohanna W. Lampe Epidemiology 28 September 2008 Pages: 587 - 594
Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer James J. DignamVanja DukicNorman Wolmark Epidemiology 02 October 2008 Pages: 595 - 602
Increasing incidence of breast cancer: distinguishing between the effects of birth cohort and a national breast screening programme Sylvia B. F. BrownDavid S. MorrisonTimothy G. Cooke Epidemiology 15 October 2008 Pages: 603 - 607
Impact of breast cancer diagnosis and treatment on work-related life and factors affecting them Eunmi AhnJuhee ChoYoung Ho Yun Epidemiology 15 October 2008 Pages: 609 - 616
Caution should be taken in the methodology used to confirm c.156_157insAlu BRCA2 mutation Patricia MachadoFatima Vaz Letter to the Editor 17 July 2008 Pages: 617 - 618
Factor V Leiden and prothrombin G20210A polymorphisms are not associated with disease-free survival in breast cancer Aydan ErogluRagip ÇamNejat Akar Letter to the Editor 06 September 2008 Pages: 619 - 620
About the c.156_157insAlu BRCA2 breast cancer predisposing mutation Erik TeugelsJacques De Grève Letter to the Editor 21 September 2008 Pages: 621 - 622
